Avorelin
Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued.
General Information
Update Date：2016-04-22
- Drug Name：
- Avorelin
- Research Code：
- EP-23904; MF-6001
- Trade Name：
- MOA：
- Luteinizing hormone releasing hormone (LH-RH) agonist
- Indication：
- Prostate cancer; Breast cancer; Endometriosis
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Mediolanum (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-15
|
Molecular Weight | 1296.48 | ||||||||||||
| Formula | C65H85N17O12 | |||||||||||||
| CAS No. | 140703-49-7 (Avorelin); | |||||||||||||
| Chemical Name | 1-9-Luteinizing hormone-releasing factor (swine), 6-(2-methyl-D-tryptophan)-9-(N-ethyl-L-prolinamide)- | |||||||||||||
| Avorelin （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||